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S. Choksy,* A.G. Pockley, Y.E. Wajeh and P. ChanDivision of Clinical Sciences (North), University of Sheffield, Clinical Sciences Centre, Northern General
Hospital, Herries Road, Sheffield S5 7AU, UKObjective. This study quantified endogenous VEGF and VEGF receptor expression in limbs of patients with chronic critical
limb ischaemia (CLI).
Methods. Skin and muscle biopsies were obtained from the legs of 25 patients undergoing limb amputation for CLI. Samples
were obtained at the amputation level (thigh or calf) and, distally, from the foot and in the vicinity of ischaemic ulcers and
gangrene. Control biopsies were obtained from patients undergoing amputation for non-arterial reasons or knee arthroplasty
(nZ7). VEGF protein levels in tissue lysates were measured by ELISA, and VEGF and KDRmRNA levels were determined
using quantitative PCR.
Results. At the amputation level, VEGF protein and VEGF and KDR mRNA levels in CLI limbs were similar to those in
controls. In the foot VEGF mRNA in skin (PZ0.005) and VEGF protein levels in muscle (PZ0.02) were elevated compared
to levels in a proximal biopsy from the same limb. VEGF and KDR mRNA levels in the vicinity of gangrene/ulcers (VEGF
PZ0.01, KDR PZ0.03) also were elevated.
Conclusions. VEGF expression is not deficient in CLI. Indeed, it is elevated at distal sites in the ischaemic limb. These
findings question the rationale for VEGF supplementation in CLI.Keywords: Therapeutic angiogenesis; Peripheral arterial disease; Collaterals; Angiogenesis; Critical limb ischaemia;
Vascular endothelial growth factor; VEGF; KDR; VEGF R2.Introduction
Vascular endothelial growth factor (VEGF) is a key
regulator of angiogenesis which is up regulated by
hypoxia.1 VEGF exists in various isoforms ranging
from 121 to 206 amino acids resulting from alternative
exon splicing.2 VEGF increases vascular permeability3
and induces the migration and proliferation of
endothelial cells.4 VEGF binds to Flt1 (fms like
tyrosine kinase receptor) and KDR (kinase insert
domain receptor) receptors present on endothelial
cells. The role of the Flt1 receptor in angiogenesis is not
clear, although it also is present on the surface of
monocytes, where it may play a role in monocyte
chemotaxis.5 KDR plays a much more definable role in
angiogenesis by mediating the full spectrum of
biological responses to VEGF including mitogenesis,
migration and survival of endothelial cells. Neuropilining author. Sohail Choksy, Division of Clinical Sciences
cal Sciences Centre, Northern General Hospital, Herries
ld S5 7AU, UK.
: sohail.choksy@sheffield.ac.uk
0660+ 10 $35.00/0 q 2004 Elsevier Ltd. All rights reseris a co-receptor for the VEGF165 isoform enhancing its
binding to KDR.6
Although the role of VEGF in arteriogenesis
(collateral vessel formation) remains disputed,7
exogenous VEGF has been shown to be capable of
stimulating collateral development in ischaemic
limbs.8 Interest in the potential clinical efficacy of
increasing endogenous levels of VEGF in patients with
peripheral vascular disease developed from encoura-
ging results in pre-clinical studies9,10 and several early
clinical reports have indicated that the administration
of VEGF by direct intra-muscular gene transfer to
patients with critical limb ischaemia (CLI) might result
in symptomatic improvement.11–15 Human CLI is
characterized by chronically hypoxic conditions that
last for weeks or even months and it might be that
endogenous VEGF expression is attenuated by chronic
hypoxia.16,17 However, the rationale for VEGF replace-
ment therapy remains to be established since little is
currently known about pre-existing levels of VEGF
and VEGF receptor expression in human CLI. Fur-
thermore, insight into endogenous levels of VEGF and
VEGF receptor expression in different parts of theEur J Vasc Endovasc Surg 28, 660–669 (2004)
doi:10.1016/j.ejvs.2004.09.001, available online at http://www.sciencedirect.com onved.
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supplementation is most likely to be therapeutically
beneficial if it is delivered to areas in which endogen-
ous expression is reduced.
Evidence from animal studies in which the femoral
artery was excised has indicated that VEGF is up-
regulated in limb ischaemia.18–21 However, the dur-
ation of ischaemia in such experimental models, is
limited and the histological features more closely
resemble those of acute limb ischaemia in humans.
Currently there is little data on tissue levels of VEGF in
different parts of the ischaemic limb in human disease.
The aim of the current study was to systematically
quantify tissue (skin and muscle) VEGF and VEGF
receptor gene and VEGF protein expression in
critically ischaemic human limbs.Materials and MethodsPatients
The characteristics of the control and CLI patients are
summarized in Tables 1 and 2. A total of 25 patients
with end-stage peripheral arterial disease were
recruited, as characterized by rest pain and, in many
cases, tissue loss (Fontaine classification, stage III and
IV). There were 14 diabetics (Table 1). All patients had
undergone angiography confirming peripheral arter-
ial disease. Eight patients experienced intractable rest
pain alone, 10 had gangrene affecting the toe(s) and
seven had ischaemic ulcers affecting the calf (nZ3),
heel (nZ2), lateral malleolus (nZ1) and arch of the
foot (nZ1). Sixteen of the patients with CLI had
undergone unsuccessful angioplasty or surgical
bypass and nine patients were considered to have
un-reconstructable disease (Table 2).
As controls, samples were collected from seven
patients without documented arterial disease. These
included three patients that had undergoneTable 1. Patient characteristics
CLI Control
Sex, M/F MZ21, FZ4 MZ5, FZ2
Median age (IQR),
years
71 (15.5) 65 (20)
Diabetes mellitus 14 1
Hypertension 10 2
Ischaemic heart dis-
ease
7 1
Renal failure 5 0
Chronic respiratory
disease
4 0
Smoker 10 1
Summary of characteristics of CLI and control patients.amputations for non-arterial causes, the indications
for which were venous disease, congenital tibial non-
union and chronic osteomyelitis. The other four
patients had undergone knee arthroplasty. During
knee arthroplasty, samples were harvested prior to
inflation of the tourniquet.
Ethical approval for the study was granted by the
North Sheffield Ethics Committee and all patients gave
full informed written consent.Sample collection
Approximately 200 mg of tissue was collected from
each site (see below). Samples were obtained immedi-
ately after amputation, snap-frozen in liquid nitrogen
and stored atK80 8C until analysis.CLI patientsProximal biopsies
Biopsies were obtained at amputation level from
clinically well-perfused skin and muscle, which
healed primarily following amputation. These were
the upper calf (gastrocnemius muscle and calf skin) in
transtibial (nZ15), and lower thigh (quadriceps and
thigh skin) in transfemoral amputations (nZ10).Distal biopsies
Distal muscle was obtained from the first layer of
muscles in the sole of the foot (flexor digitorum brevis)
in selected patients, in whom foot muscle had not been
replaced by contracture or fibrotic tissue (nZ12).
Distal skin biopsies were obtained from the dorsum
of the foot and from edges of the ischaemic ulcer or
viable skin immediately bordering gangrenous digit(s)
(nZ11). Biopsies were not obtained from areas that
exhibited macroscopic features of gross sepsis, inflam-
mation or recent scars. Therefore not all limbs could be
biopsied at all sites.Control patients
A proximal sample (quadriceps and thigh skin) was
collected from the thigh of patients undergoing
amputation for non-arterial reasons and in patients
undergoing knee arthroplasty (nZ7). Distal control
sample were obtained from the foot (dorsal skin and
flexor digitorum brevis muscle) only in patients
undergoing amputation for non-arterial reasons
(nZ3).Eur J Vasc Endovasc Surg Vol 28, December 2004
Table 2. Characteristics of patients undergoing amputation for CLI
Patient Age Sex Diabetes Indication for
amputation
Site of tissue
loss
Amputation
level
Revasc*
1 42 F N Gangrene Toe Transtibial N
2 51 M N Rest pain – Transfemoral Y
3 55 M Y Ulcer Arch of foot Transtibial N
4 58 M Y Rest pain – Transtibial Y
5 62 M N Rest pain – Transfemoral Y
6 62 M N Ulcer Calf Transfemoral Y
7 62 M Y Ulcer Calf Transfemoral Y
8 65 M N Gangrene Toes Transtibial Y
9 66 F N Rest pain – Transfemoral Y
10 66 M Y Ulcer Calf Transfemoral N
11 69 M N Gangrene and
ulcer
Three toes,
heal ulcer
Transfemoral N
12 71 F Y Gangrene Great toe Transtibial N
13 71 M Y Gangrene Great toe Transtibial N
14 72 M Y Gangrene Great toe
amputation
site
Transtibial Y
15 72 M Y Gangrene Toes Transtibial Y
16 73 M N Rest pain – Transtibial Y
17 74 M Y Rest pain – Transfemoral Y
18 75 M N Gangrene and
ulcer
Heal, toe Transtibial Y
19 77 M Y Gangrene Great toe
amputation
site
Transtibial Y
20 78 M Y Gangrene Amputation
site non-heal-
ing
Transtibial N
21 78 M Y Rest pain – Transtibial Y
22 79 M N Rest pain – Transfemoral Y
23 80 M Y Ulcer Heal Transtibial Y
24 82 M Y Ulcer Lateral aspect
heal
Transtibial N
25 85 F N Ulcer Medial mal-
leolus
Transfemoral N
CLI patients undergoing amputation.
* Indicates if patient underwent surgical or radiological intervention e.g. bypass or angioplasty. Indications for amputationwere intractable
rest pain only (nZ9) or rest pain and tissue loss (nZ16). A thigh skin andmuscle biopsywas collected frompatients undergoing transfemoral
(nZ10) and a calf skin and muscle biopsy (nZ15) in patients undergoing transtibial amputation. A foot skin biopsy was collected in most
cases (nZ22), foot muscle biopsies were collected in 12 patients and additional skin biopsies bordering ischaemic ulcers and gangrene were
collected in 10 patients.
S. Choksy et al.662VEGF and VEGF receptor gene expression
Tissue samples were weighed, an appropriate volume
of RNA extraction buffer was added (Trireagent,
Sigma, Poole, UK) and tissue was mechanically
disrupted using a polytron homogenizer (Kinematica,
Lucerne, Switzerland). Total RNA was extracted as
described previously22 and quantified by UV spectro-
photometry (Cecil Instruments Ltd, Cambridge, UK).
RNA integrity was evaluated by the presence of the
18S and 28S ribosomal bands on gel electrophoresis.
Messenger RNA levels of VEGF, KDR and the 18S
ribosomal genes were determined by real time RT-PCR
using the Taqmanw assay. Total RNA (500 ng) was
reverse transcribed into complementary DNA (cDNA)
using random hexamers (Promega UK Ltd, South-
ampton, UK), Maloney Murine Leukemia Virus
reverse transcriptase (superscript II, Invitrogen Ltd,Eur J Vasc Endovasc Surg Vol 28, December 2004Paisley, UK) and deoxyribonucleoside 5 0-triphos-
phates (dNTPs, Promega). RNA was DNAse treated
to eliminate the possibility of DNA contamination
(DNASE 1, Ambion (Europe) Ltd., Huntingdon, UK).
cDNA (1 ml) was added to a Taqmanw assay master
mix containing 12.5 ml 2X qPCR mix (Eurogentec,
Seraing, Belgium), primers [200 mM] (Sigma Genosys
Ltd), fluorogenic labeled probe [50 mM] (Oswell,
Southampton, UK) and water in a 25 ml reaction
volume. Probe and primer sequences were designed
using primer express software (Version 4, Applied
Biosystems, Foster City, California, USA).
Each sample was run in triplicate on a 384-well
plate on ABI 7900 HT sequence detection system
(Applied Biosystems) under universal cycling con-
ditions (50 8C for 2 min and 95 8C for 10 min, followed
by 40 cycles of 95 8C for 15 s and 60 8C for 1 min). Each
plate included known quantities of oliogonucleotides
VEGF and KDR Expression in Human CLI 663synthesized commercially (Sigma Genosys Ltd). Flu-
orescence was detected in real time and analyzed at
the completion of the RT-PCR reaction. A standard
curve was constructed, from which absolute copy
numbers of each gene could be calculated for each
sample. Results were normalized to those for 18S
ribosomal gene in order to correct for differences in
template loading in each sample. The intrasample
variation (coefficient of variation, CV) of the assay was
8.6%.VEGF protein levels
Tissue samples were homogenized using a lysis buffer
described by Vadivello et al.23 (50 mM Tris pH 8,
150 mM NaCl, 0.2% SDS, 0.5% Na Deoxycholate, 0.5%
Triton X-100) containing a protease:phosphatase
inhibitor cocktail (100 mM NaF, 200 mM NaVO4,
70 IU aprotinin, 10 mg/ml leupeptin, 1 mM EDTA,
0.1 mM PMSF). The homogenate was centrifuged at
3000g for 10 min and at 12,000 g for 10 min and the
supernatant was stored atK70 8C for a short time (!1
month) prior to protein content determination and
analysis by ELISA. The total protein content of the
supernatant was determined by a modified Lowry
method (DC protein assay, BioRad, Hemel Hempstead,
UK).
Total VEGF protein levels in the supernatants were
determined by enzyme immunoassay according to the
manufacturer’s protocol (Cytosetse, Biosource,
Nivelles, Belgium). Ninety six well Maxisorp micro-
titer plates (Nunc, Hereford, UK) were coated over-
night (18 h) at 4 8C with murine anti-human VEGF
monoclonal antibody (clone no. A183C-13G8) at a
concentration of 2.5 mg/ml. Non-specific binding was
blocked by incubation with phosphate buffered saline
(PBS) containing 1% v/v Tween 20 (PBS-T) and 1%
w/v bovine serum albumin, for 2 h at room tempera-
ture. VEGF standards (0–10,000 pg/ml) and samples
(100 ml) were added in duplicate and plates were
incubated for 90 min at room temperature, after which
they were washed and biotinylated polyclonal rabbit
anti-human VEGF detection antibody (100 ml,
0.5 mg/ml) was added. Plates were incubated for 1 h,
washed and a streptavidin–horseradish peroxidase
conjugate (HRP, 0.5 mg/ml) was added. After 45 min,
plates were washed and tetramethylbenzidine (TMB)
substrate was added. The enzymatic reaction was
stopped after 20 min by addition of 2 M H2SO4. The
resultant absorbances at 450 nm and 650 nm (reference
wavelength) were determined using a Titertek Mul-
tiskan MCC/340 microplate spectrophotometer
(Thermo Life Sciences, Basingstoke, Hampshire, UK).VEGF levels were calculated from the standard curve
using Ascent analysis software (Thermo Life Sciences)
and were normalized to the total protein concen-
tration. The CV for the technique was less than 10%
within the dynamic range of the assay.Statistical analysis
Non-parametric data are presented as medians (IQR,
interquartile range). Gene expression is expressed as
mRNA copies per million of 18S and protein
expression in picograms (pg) per milligram (mg) of
total protein. For statistical analysis the proximal
control biopsies from knee arthroplasty and non-
arterial amputation were grouped together and were
compared with proximal CLI biopsies using the
Mann–Whitney test. We also sought to identify regional
variation within CLI limbs in order to determine
whether there were differences along a proximal to
distal axis, corresponding to a presumed gradient of
ischaemia. These paired comparisons of data were
performed using the Wilcoxon signed rank test.
All statistical analyses were performed using
Statviewe (Abacus Concepts, Berkeley, California,
USA) and P values less than 0.05 were considered to
represent statistically significant differences.ResultsVEGF and VEGF receptor gene and VEGF protein
expression in skin
CLI vs. control
There were seven proximal skin and muscle
biopsies from controls, and VEGF and VEGF
receptor gene and VEGF protein expression in
these were compared to that in proximal biopsies
from patients with CLI (thighZ10, calfZ15). VEGF
and KDR gene expression and VEGF protein levels
in proximal skin samples from control and CLI
patients were similar (Fig. 1). In muscle VEGF gene
and protein levels were similar in proximal
biopsies in CLI and control patients (Fig. 2).
However when only thigh muscle samples were
compared KDR gene expression was reduced in
CLI patients compared to controls (control 3.2
(3.69) vs. CLI 1.65 (1.83), PZ0.016, Mann–Whitney).
Regional variation in CLI limbs
There were 22 limbs in which both a proximal (thigh or
calf) and foot skin biopsies were available, and 10
limbs from which an additional skin biopsy borderingEur J Vasc Endovasc Surg Vol 28, December 2004
Fig. 1. Box plot of VEGF and KDR mRNA expression and VEGF protein levels in proximal skin samples from critically
ischaemic limbs (thigh and calf) and controls. mRNA levels are expressed as copies normalized to 18S and VEGF protein
levels are expressed as picograms (pg) per milligram (mg) of protein. Boxes represent interquartile range (IQR), horizontal
bars represent groupmedians andwhiskers represent 5th and 95th percentiles. Filled circles represent outliers. Therewere no
statistical differences in VEGF mRNA and protein in CLI vs control in proximal skin biopsies.
S. Choksy et al.664ulcer/gangrene was available. Paired foot and
proximal muscle biopsies were available in 12
patients.
There was no significant difference in VEGF mRNA
levels between proximal skin and muscle biopsies in
transfemoral (thigh biopsies) and transtibial amputa-
tions (calf biopsies) in CLI patients (Fig. 3). However,
VEGF mRNA levels were two-fold higher in foot skin
(PZ0.005, Wilcoxon) and four-fold higher in skin
bordering ischaemic ulcers and gangrene (PZ0.01,
Wilcoxon) than those in a proximal biopsy obtained
from the same limb (Fig. 3). There was no significant
difference in VEGF mRNA levels between proximal
and distal muscle biopsies.
VEGF protein levels in skin and muscle biopsies
from the thigh and calf were similar as were VEGFFig. 2. Box plot of VEGF and KDR mRNA expression and VEG
ischaemic limbs (thigh and calf) and controls. mRNA levels a
levels are expressed as picograms (pg) per milligram (mg) of p
bars represent groupmedians andwhiskers represent 5th and 9
statistical differences in VEGF mRNA and protein in CLI vs co
KDR mRNA levels were significantly less in CLI patients than
Eur J Vasc Endovasc Surg Vol 28, December 2004protein levels in foot and proximal skin biopsies
(Fig. 4). In contrast, VEGF protein levels in foot muscle
were higher than those in the corresponding proximal
biopsy (PZ0.02, Wilcoxon; Fig. 4). Although VEGF
protein levels were elevated distally in ischaemic
ulcers and gangrene, this difference did not reach
statistical significance (PZ0.07, Wilcoxon).
There was no significant difference in KDR mRNA
levels in the skin of the thigh and calf from limbs of
patients with CLI, whereas KDR expression in the
thigh muscle was lower than that in calf muscle (PZ
0.002, Mann–Whitney, thigh vs. calf; Fig. 5).
Distally, KDR gene expression appeared elevated in
foot skin compared to proximal biopsies, although this
did not reach statistical significance (PZ0.06). How-
ever, KDR mRNA levels in skin bordering ulcers andF protein levels in proximal muscle samples from critically
re expressed as copies normalized to 18S and VEGF protein
rotein. Boxes represent interquartile range (IQR), horizontal
5th percentiles. Filled circles represent outliers. Therewere no
ntrol in proximal muscle biopsies. However, in thigh muscle
controls (PZ0.016, see text).
Fig. 3. Box plot of VEGFmRNA expression at different sites within critically ischaemic limbs. Boxes represent IQR, horizontal
bars represent groupmedians and whiskers represent 5th and 95th percentiles. Filled circles represent outliers. *PZ0.005 foot
vs proximal skin (Wilcoxon), †PZ0.01 ulcer/gangrene vs proximal skin (Wilcoxon).
VEGF and KDR Expression in Human CLI 665gangrenous areas was significantly higher than that in
proximal biopsies (PZ0.03; Fig. 5). There was no
overall difference in KDR gene expression levels
between foot and proximal muscle biopsies.
Control patients
There were three control amputees from whom a
proximal and foot biopsy was available. Unlike
ischaemic limbs, no difference was detected in VEGF
protein or VEGF/VEGF receptor gene expression in
either skin or muscle between proximal and distal
biopsies (data not shown).Fig. 4. Box plot of VEGF protein expression at different sites with
bars represent group medians and whiskers represent 5th and
vs proximal muscle (Wilcoxon).Discussion
This study has demonstrated that VEGF gene and
protein expression is greater in ischaemic skin and that
VEGF protein expression is greater in ischaemic
muscle. Importantly, these data clearly indicate that
the mechansisms for upregulation VEGF in the
ischaemic limb remain intact.
Since tissue loss affecting the skin (ulcers and
gangrene) is a common feature of critical limb
ischaemia in humans, VEGF expression in skin as
well as muscle was examined. VEGF expression inin critically ischaemic limbs. Boxes represent IQR, horizontal
95th percentiles. Filled circle represent outliers. *PZ0.02 foot
Eur J Vasc Endovasc Surg Vol 28, December 2004
Fig. 5. Box plot of KDR mRNA expression at different sites within critically ischaemic limbs. Boxes represent IQR, horizontal
bars represent group medians and whiskers represent 5th and 95th percentiles. Filled circles represent outliers. *PZ0.002
proximal muscle sample from transfemoral (thigh) vs transtibial amputees (calf) (Mann–Whitney). †PZ0.06 foot vs proximal
skin, ‡PZ0.03 ulcer/gangrene vs. proximal skin (Wilcoxon).
S. Choksy et al.666proximal control and CLI biopsies was similar;
proximal CLI biopsies were taken from relatively
well perfused skin and muscle which healed primarily
following amputation and can be regarded as ‘internal
controls’, against which distal ischaemic biopsies
could be compared. This strategy was appropriate as
it has previously been demonstrated that proximal
muscle samples from ischaemic limbs exhibit rela-
tively normal histology and low VEGF/KDR
expression.24 Another benefit of comparing a distal
sample with a corresponding proximal sample from
the same limb is that it is likely to reduce variability
resulting from patient diversity. This diversity resulted
in the considerable variation of VEGF/KDR
expression observed. Factors such as age and diabetes,
the presence of tissue loss and differences in severity
and duration of ischaemia may all contribute to
variability.
We observed that VEGF gene expression in distal
skin and VEGF protein levels in distal (foot) muscle
were about two-fold greater than in the corresponding
proximal biopsy from the same patient. This may be
partly explained by a gradient of ischaemia from
proximal to distal thereby exposing distal tissue to the
severest hypoxia. The resultant hypoxia is likely to
induce increased VEGF gene expression in keratino-
cytes, myocytes and dermal fibroblasts, which are all
known to up regulate VEGF in hypoxic conditions,
partly mediated by a transcription factor, hypoxia
inducible factor 1a (HIF1a). The levels of HIF1a levelsEur J Vasc Endovasc Surg Vol 28, December 2004are increased under hypoxic conditions. HIF1 a binds
to a HRE (hypoxia response element), an enhancer site
upstream of the VEGF gene, causing the transcrip-
tional upregulation of VEGF.25 Rissanen et al. demon-
strated that elevated HIF1a was associated with an
elevation of VEGF expression in ischaemic muscle
obtained from CLI limbs.24 In regions of tissue loss
such as margins of ulcers and skin bordering
gangrene, we found that VEGF and KDR expression
were about four times greater than corresponding
proximal biopsies. At these sites other mechanisms are
likely to contribute to VEGF up regulation such as
inflammation and wound healing. Elevated VEGF
mRNA levels have also been found in homogenates of
granulation tissue adjacent to chronic sacral pressure
ulcers26 and in hyper-plastic epithelium from wound
margins in venous ulcers.27
Although VEGF mRNA levels were elevated
significantly, there was only a tendency towards
elevated levels of VEGF protein in skin adjacent to
ulcers and gangrene (PZ0.07). The converse was
apparent in muscle, in that muscle VEGF protein
levels were elevated whereas VEGF mRNA levels
were unchanged. These inconsistencies might be
explained by the sequestration of VEGF in the extra
cellular matrix (ECM). Apart from the VEGF121
isoform which is freely diffusible, all other isoforms
of VEGF bind, to differing degrees, to the ECM.28 The
mechanisms that govern the release/storage of VEGF
isoforms from the ECM in different tissues are not fully
VEGF and KDR Expression in Human CLI 667understood and might result in a lack of association
between total VEGF protein levels and gene
expression.
Our finding that VEGF levels vary in different parts
of the ischaemic limbs is similar to that observed in a
rat model of severe limb ischaemia in which the onset
of ischaemia has been shown to be followed by a two
fold increase in VEGF in distal muscle, but no
significant increase proximally in thigh muscle.20
VEGF levels remained elevated distally up to 56
days after onset of ischaemia.
In humans, Rissanen et al.24 used semi-quantitative
methods to assess VEGF mRNA and protein
expression (in situ hybridization and immunocyto-
chemistry respectively). This localized VEGF and KDR
expression to atrophic and regenerating myocytes.
Like our study, lowest levels of VEGF and VEGF
receptor expression were observed in proximal control
samples. VEGF levels in chronically ischaemic muscle
appeared to be attenuated distally, when compared to
acute ischaemia.24 Unfortunately, this study used non-
quantitative methods to assess VEGF expression, there
were relatively few patients and no controls. More
recently Palmer-Kazen et al. used ELISA and immuno-
cytochemistry to assess VEGF and FGF protein
expression in 25 patients undergoing lower limb
bypass for CLI.29 VEGF expression was localized to
just beneath the epidermis in skin and in the periphery
of muscle fibres. However, these authors failed to
detect elevated VEGF expression distally observing
instead a reduction in skin and no difference in muscle
VEGF expression in distal compared to proximal
samples. We believe these results can be explained
by the fact that our patients had end stage CLI
representing more advanced disease than patients in
the latter study. It may also be related to the site of
harvest of our distal samples. We collected distal
samples from the foot whereas Palmar-Kazen et al.
collected distal samples from the calf, which may not
have been ischaemic enough to cause a detectable
increase in VEGF expression.
Preliminary results from several ongoing clinical
trials of VEGF gene therapy for the treatment of
peripheral vascular disease in the United States and in
Europe are encouraging.12,30 In uncontrolled series
of CLI patients a reduction in rest pain, healing of
ischaemic ulcers and possibly limb salvage was
observed.11,15 However, our study has shown that
VEGF levels are not reduced in any part of the
ischaemic limb and are indeed upregulated distally.
It is conceivable that clinical benefit might result from
VEGF over-expression. However, in addition to
stimulating angiogenesis, sustained over-expression
of VEGF may result in potentially adverse side effectsranging from oedema31 tomore harmful effects such as
formation of vascular tumors in skeletal muscle14,32
and myocardium.33 There is some evidence that VEGF
overexpression results in accelerated limb loss in
animal models by inducing muscular oedema, necro-
sis and disturbed regeneration associated with for-
mation of immature leaky blood vessels lacking
smooth muscle cells.34
An unexpected and potentially important finding of
our study is the reduction in KDR gene expression in
the thigh muscle in CLI patients compared to both
control thigh biopsies and CLI calf biopsies. KDR
mediates almost all of the angiogenic functions of
VEGF. On binding by VEGF, an array of intracellular
signal transduction pathways are stimulated, leading
to a variety of biological responses including mitogen-
esis, migration and survival of endothelial cells.25
Therefore, deficient KDR expression might limit the
effectiveness of VEGF gene therapy for critically
ischaemic limbs, although it is conceivable that
exogenous VEGF could correct reduced KDR
expression via its autocrine actions.35
Diabetes is a major risk factor for peripheral arterial
disease and a greater proportion of diabetic patients
with PVD are destined for amputation. This is
reflected in the greater proportion of patients with
diabetes in the CLI patient group. However, VEGF and
KDR gene expression in skin or muscle (proximally,
distally) from patients with diabetes and patients
without diabetes in the CLI group were similar (data
not shown). We, like others, have not shown a
decreased ability to up regulate VEGF in diabetes.29,36
In summary, VEGF is upregulated appropriately in
the ischaemic limb, which indicates that the mechan-
ism for VEGF up regulation is intact. There is a
regional variation of VEGF expression. Distally in foot
skin and muscle and in skin bordering tissue loss,
VEGF levels are elevated. However, proximally, where
collateral development is likely to be more important
VEGF levels are no different to control biopsies. There
is also a reduction in KDR expression in thigh muscle
in CLI patients.
This study has raised important questions regard-
ing VEGF biology e.g. why are high VEGF levels
distally not reflected in higher levels proximally?
Could this result from a failure of propagation?
These data question the rationale of VEGF gene
therapy. Should additional VEGF be given to ischae-
mic limbs, which already have high levels of VEGF
distally? Might supra-physiological levels of VEGF
result in side effects that could exacerbate the
symptoms of CLI such as oedema? Finally, if VEGF
gene therapy is to be used therapeutically, proximal
rather than distal supplementation is most likely to beEur J Vasc Endovasc Surg Vol 28, December 2004
S. Choksy et al.668beneficial, since VEGF levels are not elevated
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